Literature DB >> 10657752

Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR).

J C Pastor1, E Rodríguez, M A Marcos, M I Lopez.   

Abstract

PURPOSE: This study was designed to evaluate the efficacy of a combined treatment, previously used to prevent fibrosis after glaucoma surgery, to inhibit an experimental model of proliferative vitreoretinopathy (PVR).
METHODS: Two groups of albino rabbits were used. In the control group (group 1, n = 14), experimental PVR was induced using vitrectomy, retinotomies, cryotherapy and intraocular injection of platelet-rich plasma. In the experimental group (group 2, n = 15), after PVR was induced, the following treatment was administered for 4 weeks: systemic methylprednisolone, sodium diclofenac and colchicine combined with topical atropine 1%, adrenaline 10% and dexamethasone phosphate 0.1%. Follow- up consisted of fundus examination for 4 weeks. Results were classified according to Fastenberg's classification. Only retinal detachments were considered to compare the two groups. Nonparametric test was used.
RESULTS: Retinal detachments were observed in 85.7% of group 1 and 33.3% of group 2 at the end of the follow-up (p<0.01). No major systemic complications were observed.
CONCLUSIONS: Combined therapy seems to be useful for treating experimental PVR. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657752     DOI: 10.1159/000055583

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  5 in total

1.  Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial.

Authors:  Fritz Koerner; Ursula Koerner-Stiefbold; Justus G Garweg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-21       Impact factor: 3.117

2.  Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment.

Authors:  K Ghasemi Falavarjani; M Modarres
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

Review 3.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

4.  The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial.

Authors:  Ernesto Bali; Eric J Feron; Ed Peperkamp; Marc Veckeneer; Paul G Mulder; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-25       Impact factor: 3.117

5.  Protein Kinase A Inhibitor H89 Attenuates Experimental Proliferative Vitreoretinopathy.

Authors:  Yali Lyu; Wei Xu; Jieping Zhang; Mengwen Li; Qingyi Xiang; Yao Li; Tianhao Tan; Qingjian Ou; Jingfa Zhang; Haibin Tian; Jing-Ying Xu; Caixia Jin; Furong Gao; Juan Wang; Weiye Li; Ao Rong; Lixia Lu; Guo-Tong Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.